Scholarlink

Introduction <p>About 15–20% of lung neoplasms are of neuroendocrine origin. In addition to evaluation of morphological features, these neoplasms can be identified by immunohistochemistry (IHC) using antibodies against neuroendocrine markers such as synaptophysin, chromogranin A, and neural cell adhesion molecule, CD56. Recent studies have shown that insulinoma-associated protein 1 (INSM1) is increasingly used as a diagnostic marker for neoplasms of neuroendocrine origin, as it is highly sensitive and specific. The primary focus of this study was to evaluate the sensitivity and specificity of a recently developed assay that uses a new INSM1 (SP493) antibody for detecting primary neuroendocrine lung neoplasms and to compare this IHC assay with currently used neuroendocrine markers. </p> Method <p>Tissue microarrays containing 391 lung neoplasms were stained with INSM1 (SP493) antibody, INSM1 (MRQ-70) antibody, CONFIRM anti-Synaptophysin (SP11) antibody, anti-Chromogranin A (LK2H10) antibody, and CD56 (MRQ-42) antibody on BenchMark ULTRA instruments using OptiView IHC DAB Detection Kit or <i>ultra</i>View Universal DAB Detection Kit using manufacturer’s recommended protocols. Sensitivity, specificity, and accuracy were calculated for each biomarker. </p> Results <p>The sensitivity and specificity of the new assay using INSM1 (SP493) antibody for detecting primary lung neoplasms with neuroendocrine differentiation were 96.8% and 92.3%, respectively. Comparable results were seen for the lung neoplastic cases stained with INSM1 (MRQ-70) antibody, yielding a sensitivity of 94.9% and specificity of 94.1%. In contrast, the anti-Chromogranin A (LK2H10) antibody and CD56 (MRQ-42) antibody showed considerably lower sensitivities. The sensitivity was 78.7% for the anti-Chromogranin A (LK2H10) antibody and 85.4% for the CD56 (MRQ-42) antibody. However, the specificities of anti-Chromogranin A (LK2H10) antibody and CD56 (MRQ-42) antibody were comparable with the specificity of the INSM1 (SP493) antibody [91.7% for anti-Chromogranin A (LK2H10) antibody, 90.4% for CD56 (MRQ-42) antibody]. The performance of the anti-Synaptophysin (SP11) antibody was suboptimal, with a sensitivity of 82.9% and a specificity of 87.6%.</p> Conclusions <p>Overall, our data demonstrate that the IHC assay using the newly developed INSM1 (SP493) antibody is highly specific and sensitive for identifying primary neuroendocrine lung neoplasms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Novel immunohistochemical assay utilizing the INSM1 (SP493) antibody demonstrates high specificity and sensitivity in detecting primary neuroendocrine lung neoplasms

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月16日

查看全文
  • Katerina Dvorak,
  • Alexander Gomez,
  • Rafael Sainz

摘要

Introduction

About 15–20% of lung neoplasms are of neuroendocrine origin. In addition to evaluation of morphological features, these neoplasms can be identified by immunohistochemistry (IHC) using antibodies against neuroendocrine markers such as synaptophysin, chromogranin A, and neural cell adhesion molecule, CD56. Recent studies have shown that insulinoma-associated protein 1 (INSM1) is increasingly used as a diagnostic marker for neoplasms of neuroendocrine origin, as it is highly sensitive and specific. The primary focus of this study was to evaluate the sensitivity and specificity of a recently developed assay that uses a new INSM1 (SP493) antibody for detecting primary neuroendocrine lung neoplasms and to compare this IHC assay with currently used neuroendocrine markers.

Method

Tissue microarrays containing 391 lung neoplasms were stained with INSM1 (SP493) antibody, INSM1 (MRQ-70) antibody, CONFIRM anti-Synaptophysin (SP11) antibody, anti-Chromogranin A (LK2H10) antibody, and CD56 (MRQ-42) antibody on BenchMark ULTRA instruments using OptiView IHC DAB Detection Kit or ultraView Universal DAB Detection Kit using manufacturer’s recommended protocols. Sensitivity, specificity, and accuracy were calculated for each biomarker.

Results

The sensitivity and specificity of the new assay using INSM1 (SP493) antibody for detecting primary lung neoplasms with neuroendocrine differentiation were 96.8% and 92.3%, respectively. Comparable results were seen for the lung neoplastic cases stained with INSM1 (MRQ-70) antibody, yielding a sensitivity of 94.9% and specificity of 94.1%. In contrast, the anti-Chromogranin A (LK2H10) antibody and CD56 (MRQ-42) antibody showed considerably lower sensitivities. The sensitivity was 78.7% for the anti-Chromogranin A (LK2H10) antibody and 85.4% for the CD56 (MRQ-42) antibody. However, the specificities of anti-Chromogranin A (LK2H10) antibody and CD56 (MRQ-42) antibody were comparable with the specificity of the INSM1 (SP493) antibody [91.7% for anti-Chromogranin A (LK2H10) antibody, 90.4% for CD56 (MRQ-42) antibody]. The performance of the anti-Synaptophysin (SP11) antibody was suboptimal, with a sensitivity of 82.9% and a specificity of 87.6%.

Conclusions

Overall, our data demonstrate that the IHC assay using the newly developed INSM1 (SP493) antibody is highly specific and sensitive for identifying primary neuroendocrine lung neoplasms.